Brief takes for Thursday: TimeDoc’s well timed $48M, Glooko buys France’s DIABNEXT, Jio Well being’s $20M, Pear’s Tokyo sleep-wake, Antidote’s $22M, and Centene’s new, younger CEO alerts huge modifications


TimeDoc Well being, a Chicago-based digital care administration platform that allows docs to handle their affected person populations between visits, has raised $48.5 million in a Sequence B funding spherical led by Aldrich Capital Companions.  This follows on a modest $5.7 million Sequence A spherical and equally modest seed rounds (Crunchbase). (This Editor notes that funding is changing into extra modest this 12 months anyway.) TimeDoc supplies distant affected person monitoring (RPM), continual care administration, and behavioral well being monitoring, plus about 150 care coordinators who do it. The funding can be so as to add 20-40 new hires to the care coordinator group month-to-month and undoubtedly construct out inside and with out its current 35 state protection. The 2025 aim acknowledged by their CEO is to serve a million sufferers month-to-month. Axios, Mobihealthnews

Palo Alto meets Paris, with Glooko shopping for DIABNEXT. The French firm, which had been advertising its personal diabetes administration app, can be rebranding as GlookoXT, use the Glooko platform and proceed to market its established app and distant monitoring merchandise. Phrases weren’t disclosed, however the DIABNEXT crew can be becoming a member of the Glooko crew. Glooko’s been hitting the European capitals, since final month they acquired Berlin-based xbird.  Launch, Mobihealthnews

In Asia-Pacific information, Jio Well being, primarily based in Vietnam, now has $20 million in a Sequence B funding led by Singapore’s Heritas Capital. The startup is an fascinating mix of telemedicine and e-prescribing through app, bodily “good” clinics, 300 branded pharmacies, and on-demand dwelling care. Mobihealthnews

Sleepless in Tokyo? In Japan, Pear Therapeutics and SoftBank are teaming as much as develop a digital therapeutic treating sleep-wake problems. Pear has an FDA-approved prescription product for continual insomnia, Somryst, and is pursuing a technique of selling sleep remedies in nations outdoors the US. Pear went public through a SPAC at finish of 2021. Mobihealthnews

Telehealth continues to be charming traders, with a $22 million Sequence A elevate by the curiously named Antidote Well being. This tops off $12 million in seed funding by iAngels, Group 11, and Flint Capital. Their digital consults are pitched as inexpensive both on a one-time or subscription foundation. The elevate will go in direction of including continual and first care providers, plus R&D exercise, which incorporates superior AI screening and medical choice help system capabilities constructed on a claimed 20 12 months database.

And for these of us who’re survivors of US well being plans, prime payer Centene, after 25 years of 1 man on the prime, now has a brand new CEO, efficient instantly. To nobody’s nice shock, the decide is Sarah London, previously vice chair of the Centene board of administrators, one-third of their ‘worth creation workplace’, and a part of the Workplace of the Chairman. London beforehand headed Centene’s non-plan, primarily technology-based companies. In 2020, she joined Centene from Optum Ventures, UnitedHealth’s VC arm, and previous to that was chief product officer of Optum Analytics. She suits an image of Centene being a know-how firm for value-based care that additionally owns well being plans, as soon as sketched out by their now former CEO, Michael Neidorff.

Neidorff was a casualty of December’s shakeup by activist investor Politan Capital Administration, together with three board members over the now-mandatory age 75 restrict [TTA 18 Dec 21]. Since February, Neidorff has been on medical depart of absence from the BOD chairman’s place, with James Dallas, previously of Medtronic, now appearing chair. Neidorff is now 79 so wouldn’t have the ability to stay on the board except an exception is made. He stays one among Centene’s largest particular person shareholders, although he has offered thousands and thousands of {dollars} of shares lately. We want him a speedy restoration and a quiet retirement.

London’s youth at 41 and quick rise is a seismic change for Centene, and this Editor predicts loads of modifications to come back rapidly from prime to backside, together with holdings, location, group, and tradition. Centene launch, Healthcare Dive  Disclosure: this Editor labored for a division of WellCare that was acquired by Centene, and remained with the corporate for six months after the closing.


Supply hyperlink